Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes ProjectLindsay M. Morton, Andrew L. Feldman, Jacqueline Clavel et al.|JNCI Monographs|2014Cited by 334
Disease-Free Survival Advantage of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Patients With Node-Negative, Rapidly Proliferating Breast Cancer: A Randomized Multicenter StudyDino Amadori, Annalisa Volpi, Oriana Nanni et al.|Journal of Clinical Oncology|2000Cited by 58
<i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 SubtypeValentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|Clinical Cancer Research|2020Cited by 21
41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trialPierFranco Conte, Valentina Guarneri, Antonio Frassoldati et al.|Annals of Oncology|2021Cited by 5
19P PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER studyValentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|Annals of Oncology|2020Cited by 3